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Information on a possible association between botulinum toxin treatment and 
alopecia
Alopecia is the general medical term for ‘hair loss, which can refer to a small bald 
patch of hair to total loss of hair.  Although alopecia is not damaging to your 
physical health, hair loss can have effects on your emotional health and quality 
of life.
The manufacturers of Botox® acknowledge that alopecia is a common adverse 
effect (meaning it affects between 1 in 10 and 1 in 100 people) following 
treatment of primary hyperhidrosis of the axillae.[1] The manufacturers do not 
state the location of the alopecia following treatment of primary hyperhidrosis of 
the axillae but it would be fair to suggest that as alopecia is not reported as an 
adverse effect for any other indication it would be fair to suggest that the 
alopecia occurs in the area of treatment, i.e. the axillae. In addition they note 
that alopecia has been reported as an adverse effect since Botox® has been 
marketed, although the manufacturers do not state the indication for Botox® nor 
the area of body affected by alopecia.[1]
A search of the literature did not identify any specific reports of alopecia on the 
scalp associated with the administration of botulinum toxin for cervical dystonia 
or spasticity. There was one case report of unilateral madarosis (loss of the 
eyelashes) and facial alopecia, which was presumed to be secondary to 
botulinum toxin type A injections, used for the treatment of left oromandibular 
dystonia.[2] Review articles discussing drugs known to cause alopecia do not 
include botulinum toxin as a potential cause however.[3,4] Interestingly, there 
are a few published studies investigating the use of local botulinum toxin for the 
treatment of alopecia on the scalp; the efficacy and mechanism of action for this 
treatment are unclear. [5-7]
In conclusion, a literature search did not identify any reports indicating that the 
administration of botulinum toxin for cervical dystonia or spasticity is associated 
with alopecia on the scalp. The relevance of reports following botulinum toxin 
marketing, documenting alopecia as an adverse effect, remain unclear.
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